Company also reports positive data from trial of combination treatment for a form of prostate cancer Pfizer Inc.'s stock dipped 2.5% Thursday after two of its former executives said they would not ...
Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last ...
Can-Fite is now completing all the preparatory work for a Phase II study in patients with pancreatic cancer. The study will be a multicenter open-label trial in patients with advanced pancreatic ...
This pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential eligibility for bisphosphonate treatment. Results showing the clinical utility ...